跳转至内容
Merck
CN

Z-902

Supelco

Zopiclone-D4 solution

100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H13ClN6O3D4
分子量:
392.83
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

certified reference material

质量水平

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

100 μg/mL in acetonitrile

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

−20°C

SMILES字符串

O=C1C2=NC=CN=C2C(OC(N3C([2H])([2H])CN(C)CC3([2H])[2H])=O)N1C4=NC=C(Cl)C=C4

InChI

1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/i8D2,9D2

InChI key

GBBSUAFBMRNDJC-LZMSFWOYSA-N

一般描述

This internal standard is suitable for many LC/MS and GC/MS applications including forensic analysis, clinical toxicology, urine drug testing, or isotope dilution methods. Zopiclone is a non-benzodiazepine hypnotic sold under the trade names Imovane® and Zimovane and is prescribed for the treatment of insomnia.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Imovane is a registered trademark of Sanofi-Aventis
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

FlameExclamation mark

警示用语:

Danger

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

35.6 °F - closed cup

闪点(°C)

2 °C - closed cup

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

O A H Reneerkens et al.
Psychopharmacology, 225(2), 303-312 (2012-08-03)
Sensory gating is an adaptive mechanism of the brain to prevent overstimulation. Patients suffering from clinical disorders such as Alzheimer's disease or schizophrenia exhibit a deficit in gating, which indicates not only an impairment in basic information processing that might
Kristina Y Rust et al.
Therapeutic drug monitoring, 34(6), 729-735 (2012-11-07)
Phosphodiesterase type 5 inhibitors such as sildenafil, vardenafil, and tadalafil are a class of drugs used primarily in the treatment of erectile dysfunction. Sildenafil and tadalafil are also approved for the treatment of pulmonary hypertension. The aim of this study
Osama Shaeer
The journal of sexual medicine, 10(2), 532-540 (2012-10-24)
Utility of phosphodiesterase inhibitors (PDEi's) for the treatment of erectile dysfunction (ED) has been the focus of experimental and clinical studies. However, public preferences, attitudes, and experiences with PDEi's are rarely addressed from a population/epidemiology viewpoint. The Global Online Sexuality
I A Korneev
Urologiia (Moscow, Russia : 1999), (2)(2), 106-108 (2013-06-26)
The arsenal of professionals providing assistance to men with erectile dysfunction includes a new, mouth dissolving dosage form of the vardenafil--levitra ODT. This form is effective, safe, and has a higher bioavailability as compared to vardenafil in the form of
JinQiu Yuan et al.
European urology, 63(5), 902-912 (2013-02-12)
Phosphodiesterase type 5 inhibitors (PDE5-Is) are currently the first-line therapy for erectile dysfunction (ED), but available studies investigating the comparative effects of different PDE5-Is are limited. To compare the efficacy and safety of different classes of oral PDE5-Is for ED.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门